CN1720962A - Dripping pills for tonifying kidney and strengthening bone and method for preparing the same - Google Patents
Dripping pills for tonifying kidney and strengthening bone and method for preparing the same Download PDFInfo
- Publication number
- CN1720962A CN1720962A CN 200510088712 CN200510088712A CN1720962A CN 1720962 A CN1720962 A CN 1720962A CN 200510088712 CN200510088712 CN 200510088712 CN 200510088712 A CN200510088712 A CN 200510088712A CN 1720962 A CN1720962 A CN 1720962A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- drug extract
- substrate
- extract
- dripping pills
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a drop pill of medicinal composition for treating various tuberculosis and lepromatous leprosy, which has the advantages of high biological availability, quick-speed medicine release, quick-speed effect, higher medicinal content, accurate administration dosage, low price, no acute allergic reaction or adverse effect, and facilitated transportation and carrying. The drop pill is prepared from the extract containing the active constituent of the five Chinese medicinal herbs, i.e. notoginseng, astragalus root, drynaria, frankincense, myrrh, and medicinal carrying agent as the base material.
Description
Technical field
The present invention relates to a kind of benefiting QI and nourishing blood that has, invigorating the kidney and strengthening the bones, function of promoting blood circulation to disperse blood clots, the pharmaceutical composition that is used for the sick treatment of various tuberculosis and lepromatous leprosy is a kind of drug composition oral preparation that feedstock production forms with the extract that contains 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha particularly.
Background technology
According to drug standard WS promulgated by the ministries or commissions of the Central Government
3The GULAODI ZHUSHEYE that the preparation method that provides among-the B-3947-98 is prepared from is a kind of benefiting QI and nourishing blood that has, invigorating the kidney and strengthening the bones, function of promoting blood circulation to disperse blood clots, the pure Chinese medicine injection that is used for disease treatments such as various tuberculosis and lepromatous leprosy disease, through clinical verification, determined curative effect is the common drug that clinical and family is used for the treatment of this type of disease.
Below be drug standard WS
3Prescription that provides among-the B-3947-98 and technology and brief description:
Prescription: Radix Notoginseng 100g, Radix Astragali 10g, Rhizoma Drynariae 100g, Olibanum (system) 100g, Myrrha (processed) 100g
Method for making: the above five tastes, get Radix Notoginseng powder and be broken into coarse powder, decoct with water secondary, each 2 hours, filter, merging filtrate, medicinal residues add the Radix Astragali, Rhizoma Drynariae, decoct with water secondary, each 1 hour, filter, filtrate and above-mentioned Radix Notoginseng filtrate merge, and being concentrated into relative density is 1.15～1.20, stir to add 2 times of amount ethanol down, mixing left standstill 48 hours, filtered, filtrate recycling ethanol is not to there being the alcohol flavor, and stirring adds 3 times of amount ethanol, mixing down, left standstill 24 hours, and filtered, filtrate recycling ethanol is to there not being the alcohol flavor, add the injection water to 300ml, mixing left standstill 24 hours, filter, filtrate adds 0.2% injection-use activated carbon, mixing, boiled 15 minutes, and filtered, standby; Get Olibanum, Myrrha is ground into coarse powder, extracts secondary with 70% alcohol heating reflux, each 2 hours, filter, merging filtrate reclaims ethanol to there not being the alcohol flavor, add the injection water to 200ml, mixing is transferred pH value to 8.5～9.0 with 10% sodium hydroxide solution, cold preservation was placed 24 hours, filter, merge mixing with above-mentioned reserve liquid, transfer pH value to 7.5～8.0 with 10% sodium hydroxide, filter, filtrate adds glucose for injection 50g, polyoxyethylene sorbitan monoleate 20ml, benzyl alcohol 10ml, stirring makes dissolving, adds the injection water to 1000ml, filters, embedding, promptly.
Function cures mainly: benefiting QI and nourishing blood, invigorating the kidney and strengthening the bones, blood circulation promoting and blood stasis dispelling.Be used for tuberculosis of bone and joint, lymphoid tuberculosis, diseases such as various tuberculosis such as pulmonary tuberculosis and lepromatous leprosy disease.
Owing to reasons such as technologies of preparing, the research of the compatibility of Chinese medicine injection can not show a candle to Western medicine, and causes allergy easily.Existing FUFANG BANBIANLIAN ZHUSHEYE does not still have similar other dosage form listings at present.This kind Chinese medicine is an effective component extracting from Chinese crude drug, the intravital concentrated solution of Gong the injection of making.Because the extensive use of modern biotechnology in the natural drug exploitation, the domestic herbal species that is used to inject is more and more, and application is more and more wider clinically, and adverse reaction rate also increases.According to data: the dosage form of Chinese patent medicine adverse reaction rate is that injection accounts for 31% successively, tablet accounts for 24%, pill accounts for 10%.Chinese medicine untoward reaction consequence is serious, and Chinese medicine and preparation thereof cause anaphylactic shock and rank first place, and the trend that increases is arranged year by year, this with use clinically more relevant.Chinese medicine composition more complicated is injected human body with this mixture from blood vessel, forces human body to go metabolism, and itself has just had potential danger, if again with the other medicines compatibility, contingent reaction often is difficult to prediction.The compatibility difficulty of Chinese medicine is bigger, and incompatibility is studied the compatibility of Chinese medicine without ready patterns to follow, and it is perfect also to can not show a candle to Western medicine.Chinese medicine injection causes allergy easily, and reason is to contain albumen, polysaccharide, polypeptide etc. in its composition; The purity of extracting is not enough; Plurality of Chinese is extracted, and each composition interacts; Contain cosolvent, solubilizing agent etc.
In addition, the oral formulations of the oral formulations of most drug, especially Chinese medicine exists all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.Simultaneously, conventional peroral dosage form, regular meeting produces bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.The production technology of conventional oral formulations is more complicated also, and production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
Purpose of the present invention, be to replenish the existing deficiency that is used for the oral drug preparation of various tuberculosis and the sick treatment of lepromatous leprosy, a kind of bioavailability height is provided, and has a quick release, produce effects fast, medicament contg height, take accurate measurement, cheap, no acute allergic reaction or untoward reaction, and be convenient to the dripping pills that transports and carry.Dripping pills involved in the present invention is a raw material with the extract that contains 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha, is prepared from the pharmaceutically suitable carrier as substrate.
Be prepared by the following technical solutions, can obtain dripping pills involved in the present invention:
[preparation method]
1. raw material: the extract thick paste or the dry powder that contain 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha;
2. substrate: the mixture of one or more in pharmaceutically suitable carrier such as polyethylene glycols, sorbitol anhydride class, polyoxyethylene sorbitol acid anhydride class, polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
More preferred ratio range is: drug extract: substrate=1: 1～1: 5;
4. according to the given ratio of prescription, accurately take by weighing drug extract and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine, TZDW-1 type drop pill machine as Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production, and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on 50 ℃～90 ℃, the temperature cooling of condensing agent also remains on 40 ℃～-5 ℃;
6. when treating in dropping-pill machine head and the condensation column that the temperature of condensing agent reaches desired state of temperature respectively, to contain fused solution and/or the emulsion and/or the suspension of drug extract and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent, cooling is shunk and is shaped, promptly.
Annotate: described condensing agent is any one or the two or more mixture in liquid paraffin, methyl-silicone oil, the vegetable oil.
[appendix: a kind of Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, the preparation method of Myrrha extract] be unit with g or kg, according to the weight portion meter, get 10 parts of Radix Notoginseng, 1 part of the Radix Astragali, 10 parts of Rhizoma Drynariae, 10 parts of Olibanums, 10 parts of Myrrhas, the above five tastes are got Radix Notoginseng powder and are broken into coarse powder, decoct with water secondary, each 2 hours, filter, merging filtrate, medicinal residues add the Radix Astragali, Rhizoma Drynariae, decoct with water secondary, each 1 hour, filter, filtrate and above-mentioned Radix Notoginseng filtrate merge, being concentrated into relative density is 1.15～1.20, stirs to add 2 times of amount ethanol, mixing down, left standstill 48 hours, filter, filtrate recycling ethanol is to there not being the alcohol flavor, and is standby; Get Olibanum, Myrrha is ground into coarse powder, extracts secondary with 70% alcohol heating reflux, each 2 hours, filter, merge secondary filtrate, reclaim ethanol, merge with preceding filtrate to there not being the alcohol flavor, stir, be condensed into relative density and be 1.25～1.35 thick paste, promptly get the drug extract thick paste; Or continue to make drying, and be ground into dry powder, promptly get drug extract dry powder.
[beneficial effect]
According to drug standard WS promulgated by the ministries or commissions of the Central Government
3The GULAODI ZHUSHEYE that the preparation method that provides among-the B-3947-98 is prepared from is a kind of benefiting QI and nourishing blood that has, invigorating the kidney and strengthening the bones, function of promoting blood circulation to disperse blood clots, the pure Chinese medicine injection that is used for disease treatments such as various tuberculosis and lepromatous leprosy disease, through clinical verification, determined curative effect is the common drug that clinical and family is used for the treatment of this type of disease.
Owing to reasons such as technologies of preparing, the research of the compatibility of Chinese medicine injection can not show a candle to Western medicine, and causes allergy easily.Existing FUFANG BANBIANLIAN ZHUSHEYE does not still have similar other dosage form listings at present.This kind Chinese medicine is an effective component extracting from Chinese crude drug, the intravital concentrated solution of Gong the injection of making.Because the extensive use of modern biotechnology in the natural drug exploitation, the domestic herbal species that is used to inject is more and more, and application is more and more wider clinically, and adverse reaction rate also increases.According to data: the dosage form of Chinese patent medicine adverse reaction rate is that injection accounts for 31% successively, tablet accounts for 24%, pill accounts for 10%.Chinese medicine untoward reaction consequence is serious, and Chinese medicine and preparation thereof cause anaphylactic shock and rank first place, and the trend that increases is arranged year by year, this with use clinically more relevant.Chinese medicine composition more complicated is injected human body with this mixture from blood vessel, forces human body to go metabolism, and itself has just had potential danger, if again with the other medicines compatibility, contingent reaction often is difficult to prediction.The compatibility difficulty of Chinese medicine is bigger, and incompatibility is studied the compatibility of Chinese medicine without ready patterns to follow, and it is perfect also to can not show a candle to Western medicine.Chinese medicine injection causes allergy easily, and reason is to contain albumen, polysaccharide, polypeptide etc. in its composition; The purity of extracting is not enough; Plurality of Chinese is extracted, and each composition interacts; Contain cosolvent, solubilizing agent etc.
In addition, the oral formulations of the oral formulations of most drug, especially Chinese medicine exists all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.Simultaneously, conventional peroral dosage form, regular meeting produces bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.The production technology of conventional oral formulations is more complicated also, and production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Dripping pills involved in the present invention is compared the following beneficial effect of tool with GULAODI ZHUSHEYE:
1. dripping pills involved in the present invention; utilize surfactant to be substrate; make solid dispersion with the extract that contains 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases; and substrate is hydrophilic; medicine had wetting action; can make medicine molten microgranule or the solution of loosing into rapidly; thereby make the dissolving of medicine and absorb quickening; thereby improved bioavailability, brought into play efficient, quick-acting effects etc.
2. dripping pills involved in the present invention, contact promptly with saliva and to dissolve rapidly, and absorb by oral mucosa, not only rapid-action, and the influence of not taken food, promptly all can containing take after meal ante cibum, can not produce any residual harmful substance at gastric yet, thereby make that patient's medication is safer, also have medication convenience, characteristic of accurate simultaneously.
3. dripping pills involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. dripping pills involved in the present invention, stable in properties than injection, has the anaphylaxis of not being prone to, and side effect is little, also has advantages such as high bioavailability simultaneously.
5. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
6. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind, and compares with oral liquid, and the dosage of drop pill is accurate, thereby makes the patient take metering control easily.
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of dripping pills of the present invention.
[first group: the test of single-matrix]
1. raw material: make the extract dry powder that contains 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha earlier according to [appendix], standby;
2. substrate: Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the dripping pills of different size.
[result of the test]
Test 1: is unit in qualitative difference with g or kg in order to observe drug extract and different substrates prepared dripping pills when 1: 1 the proportioning, according to 1: 1 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 13 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 13 groups of different experimental results and see Table 1.
Test 2: is unit in qualitative difference with g or kg in order to observe drug extract and different substrates prepared dripping pills when 1: 3 the proportioning, according to 1: 3 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 13 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 13 groups of different experimental results and see Table 2.
Test 3: is unit in qualitative difference with g or kg in order to observe drug extract and different substrates prepared dripping pills when 1: 9 the proportioning, according to 1: 9 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 13 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 13 groups of different experimental results and see Table 3.
[second group: the test of mixed-matrix]
1. raw material: make the extract dry powder that contains 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha earlier according to [appendix], standby;
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the dripping pills of different size.
[result of the test]
Test 4: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 1 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 4.
Test 5: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 3 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 5.
Test 6: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 9 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 6.
Test 7: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 1 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 7.
Test 8: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 3 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 8.
Test 9: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 9 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 9.
Test 10: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 1 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 10.
Test 11: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 3 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 11.
Test 12: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained dripping pills when 1: 9 proportioning, with g or kg is unit, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 12.
The group practices of table 1 drug extract and single-matrix
(drug extract: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 50.0 | 67 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 50.0 | 81 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 6000 | 50.0 | 81 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 10000 | 50.0 | 83 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 20000 | 50.0 | 80 | ＜30 | ＞10 | ++ |
| Span 40 | 50.0 | 60 | ＜30 | ＞10 | ++ |
| Polyoxyethylene stearate 40 esters | 50.0 | 80 | ＜30 | ＞10 | + |
| Poloxamer | 50.0 | 81 | ＜30 | ＞10 | + |
| Sodium lauryl sulphate | 50.0 | 62 | ＞30 | ＞10 | ++ |
| Stearic acid | 50.0 | 61 | ＞30 | ＞10 | ++ |
| Sodium stearate | 50.0 | 60 | ＞30 | ＞10 | + |
| Glycerin gelatine | 50.0 | 60 | ＞30 | ＞10 | + |
| Lac | 50.0 | 59 | ＞30 | ＞10 | + |
The group practices of table 2 drug extract and single-matrix
(drug extract: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 25.0 | 78 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 25.0 | 87 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 25.0 | 89 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 25.0 | 89 | ＜30 | ＜10 | +++ |
| Span 40 | 25.0 | 63 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 25.0 | 83 | ＜30 | ＞10 | ++ |
| Poloxamer | 25.0 | 87 | ＜30 | ＜10 | +++ |
| Sodium lauryl sulphate | 25.0 | 74 | ＞30 | ＞10 | +++ |
| Stearic acid | 25.0 | 74 | ＞30 | ＞10 | +++ |
| Sodium stearate | 25.0 | 70 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 25.0 | 70 | ＞30 | ＞10 | +++ |
| Lac | 25.0 | 71 | ＞30 | ＞10 | ++ |
The group practices of table 3 drug extract and single-matrix
(drug extract: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 10.0 | 85 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 10.0 | 91 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 10.0 | 89 | ＜30 | ＜10 | +++ |
| Span 40 | 10.0 | 67 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 10.0 | 85 | ＜30 | ＜10 | ++ |
| Poloxamer | 10.0 | 89 | ＜30 | ＜10 | +++ |
| Sodium lauryl sulphate | 10.0 | 75 | ＞30 | ＞10 | +++ |
| Stearic acid | 10.0 | 74 | ＞30 | ＞10 | +++ |
| Sodium stearate | 10.0 | 73 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 10.0 | 73 | ＞30 | ＞10 | +++ |
| Lac | 10.0 | 72 | ＞30 | ＞10 | ++ |
The group practices of table 4 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 50 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 50 | 84 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 50 | 83 | ＜30 | ＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 50 | 76 | ＜30 | ＞10 | + |
The group practices of table 5 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 25 | 89 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 25 | 88 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 25 | 87 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 25 | 82 | ＜30 | ＞10 | ++ |
The group practices of table 6 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 10 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 10 | 85 | ＜30 | ＞10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 10 | 83 | ＜30 | ＞10 | +++ |
The group practices of table 7 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 50 | 90 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 50 | 88 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 50 | 86 | ＜30 | ＜10 | ++ |
The group practices of table 8 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 25 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 25 | 90 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 25 | 89 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 25 | 89 | ＜30 | ＜10 | +++ |
The group practices of table 9 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 10 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 10 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 10 | 88 | ＜30 | ＜10 | +++ |
The group practices of table 10 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 50 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 50 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 50 | 87 | ＜30 | ＞10 | +++ |
The group practices of table 11 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 25 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 25 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 25 | 89 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 25 | 87 | ＜30 | ＜10 | +++ |
The group practices of table 12 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 10 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 10 | 89 | ＜30 | ＜10 | +++ |
1. can be seen by the result in the table: when the ratio of drug extract and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all undesirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of drug extract and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of drug extract and substrate is 1: 9, the rounding rate, the ball method of double differences is different and index such as hardness improves not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly is out of shape, " ++ " expression distortion of firmly pressing, and " +++" expression is indeformable by it.
Claims (6)
1. one kind is used for various tuberculosis and the sick pharmaceutical composition dripping pills for the treatment of of lepromatous leprosy, with the extract that contains Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha etc. 5 flavor active ingredient of Chinese herbs is raw material, be prepared from pharmaceutically suitable carrier as substrate, wherein:
1.1 substrate is selected polyethylene glycols, sorbitol anhydride class, polyoxyethylene sorbitol acid anhydride class, polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac, the mixture of one or more in above-mentioned pharmaceutically suitable carrier for use;
1.2 proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9.
2. dripping pills as claimed in claim 1, it is characterized in that the described Radix Notoginseng that contains, the Radix Astragali, Rhizoma Drynariae, Olibanum, the extract of 5 flavor active ingredient of Chinese herbs such as Myrrha is made by following method: with g or kg is unit, according to the weight portion meter, get 10 parts of Radix Notoginseng, 1 part of the Radix Astragali, 10 parts of Rhizoma Drynariae, 10 parts of Olibanums, 10 parts of Myrrhas, the above five tastes, get Radix Notoginseng powder and be broken into coarse powder, decoct with water secondary, each 2 hours, filter, merging filtrate, medicinal residues add the Radix Astragali, and Rhizoma Drynariae decocts with water secondary, each 1 hour, filter, filtrate and above-mentioned Radix Notoginseng filtrate merge, and being concentrated into relative density is 1.15～1.20, stir and add 2 times of amount ethanol down, mixing left standstill 48 hours, filtered, filtrate recycling ethanol is to there not being the alcohol flavor, and is standby; Get Olibanum, Myrrha is ground into coarse powder, extracts secondary with 70% alcohol heating reflux, each 2 hours, filter, merge secondary filtrate, reclaim ethanol, merge with preceding filtrate to there not being the alcohol flavor, stir, be condensed into relative density and be 1.25～1.35 thick paste, promptly get the drug extract thick paste; Or continue to make drying, and be ground into dry powder, promptly get drug extract dry powder.
3. dripping pills as claimed in claim 1 is characterized in that: described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or Polyethylene Glycol and poloxamer or Polyethylene Glycol and carboxymethyl starch sodium or Polyethylene Glycol and betacyclodextrin; With g or kg is unit, and by weight, its mixed proportion is polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: Polyethylene Glycol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10.
4. as claim 1 or 3 described any dripping pills, it is characterized in that: the mixed proportion of described drug extract and substrate is 1: 1～1: 5.
5. the preparation method of a dripping pills is characterized in that being made of following process:
5.1 raw material: the extract thick paste or the dry powder that contain 5 flavor active ingredient of Chinese herbs such as Radix Notoginseng, the Radix Astragali, Rhizoma Drynariae, Olibanum, Myrrha;
5.2 substrate: the mixture of one or more in pharmaceutically suitable carrier such as polyethylene glycols, sorbitol anhydride class, polyoxyethylene sorbitol acid anhydride class, polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
5.3 proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
5.4, accurately take by weighing drug extract and substrate according to the given ratio of prescription, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5.5 adjust the temperature control system of drop pill machine, make the water dropper temperature heating of drop pill machine and remain on 50 ℃～90 ℃, the temperature cooling of condensing agent also remains on 40 ℃～-5 ℃;
5.6 when treating in dropping-pill machine head and the condensation column that the temperature of condensing agent reaches desired state of temperature respectively, to contain fused solution and/or the emulsion and/or the suspension of drug extract and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent, cooling is shunk and is shaped, promptly.
6. as the preparation method of dripping pills as described in the claim 5, it is characterized in that: described condensing agent be methyl-silicone oil or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510088712 CN1720962A (en) | 2005-07-29 | 2005-07-29 | Dripping pills for tonifying kidney and strengthening bone and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510088712 CN1720962A (en) | 2005-07-29 | 2005-07-29 | Dripping pills for tonifying kidney and strengthening bone and method for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1720962A true CN1720962A (en) | 2006-01-18 |
Family
ID=35911799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510088712 Pending CN1720962A (en) | 2005-07-29 | 2005-07-29 | Dripping pills for tonifying kidney and strengthening bone and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1720962A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631401A (en) * | 2012-05-14 | 2012-08-15 | 陕西中医学院制药厂 | Chinese herba preparation for treating tuberculosis and preparation method of Chinese herba preparation |
-
2005
- 2005-07-29 CN CN 200510088712 patent/CN1720962A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631401A (en) * | 2012-05-14 | 2012-08-15 | 陕西中医学院制药厂 | Chinese herba preparation for treating tuberculosis and preparation method of Chinese herba preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1301098C (en) | Hairy holly root drip pill and its preparation method | |
| CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN1316960C (en) | Compound mactra clam drip pill and its preparation method | |
| CN1682923A (en) | Body strengthening dripping pill for invigorating qi and refreshing and its preparing method | |
| CN1301100C (en) | Nauclea officinalis drip pill and its preparation method | |
| CN1301099C (en) | Earthworm drip pill and its preparation method | |
| CN100375616C (en) | Bone strengthening dripping pills with Premena fulva craib as raw material and method for preparing the same | |
| CN1316959C (en) | Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method | |
| CN1698785A (en) | Dripping pills of abastard speedwell and its preparation process | |
| CN1720962A (en) | Dripping pills for tonifying kidney and strengthening bone and method for preparing the same | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1292738C (en) | Ginseng-pilose antler dripping pill for tonifying heart and kidney and its preparing method | |
| CN1682804A (en) | Oral administration dripping pill for nourishing heart to calm mind and its preparing method | |
| CN1720950A (en) | Compound drop pills of Chinese angelica and its preparation method | |
| CN1660361A (en) | Cold drop pills of mulberry and ginger in use for eliminating draft, clearing away heat, and preparing method | |
| CN1301107C (en) | Xiyanping drop pills of possessing function of clearing away heat and toxic materia and preparation method | |
| CN1634145A (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN1686384A (en) | Guanxinning drip pill for treating heart disease and its preparation method | |
| CN1682920A (en) | Anshenning dripping pill for treating neurosism and its preparing method | |
| CN1679673A (en) | Isatis root drops and preparation thereof | |
| CN1698821A (en) | 'Ganjing' dripping pills for treating liver disease and its preparation | |
| CN1709411A (en) | liver-clearing dropping pill for treating hepatitis and its preparing method | |
| CN1682822A (en) | Bupleurum root and asarum herb dripping pill and its preparing method | |
| CN1292740C (en) | Ginseng and Chinese angelica root dripping pill and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |